Tarlatamab-dznl

(Tarlatamab)

Phase 3Monoclonal antibody

Tarlatamab is used to treat a type of blood cancer called relapsed or refractory diffuse large B-cell lymphoma, which is a cancer of immune cells that has either come back after treatment or stopped responding to standard treatments.[1] Tarlatamab-dznl is currently being investigated across 10 indications[3], with its most advanced program in Phase 3.[1]

Tarlatamab-dznl is one of 219 small molecule programs targeting Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

218

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Brain CancerActive, not recruiting

Neuroendocrine CarcinomaActive, not recruiting

Metastatic Prostate CancerActive, not recruiting

Prostate CancerActive, not recruiting

Small Cell Lung CancerRecruiting

Limited-Stage Small-Cell Lung CancerRecruiting

Extensive Stage Lung Small Cell CancerRecruiting

Extensive Stage Lung Small Cell CarcinomaRecruiting

Extensive-Stage Small-Cell Lung CancerActive, not recruiting

Lung CancerPhase 2

Active, not recruiting

Brain CancerPhase 2

Active, not recruiting

Neuroendocrine CarcinomaPhase 3

Active, not recruiting

Metastatic Prostate CancerPhase 2

Active, not recruiting

Prostate CancerPhase 1

Active, not recruiting

Small Cell Lung CancerPhase 3

Recruiting

Limited-Stage Small-Cell Lung CancerPhase 2

Recruiting

Extensive Stage Lung Small Cell CancerPhase 2

Recruiting

Extensive Stage Lung Small Cell CarcinomaPhase 2

Recruiting

Extensive-Stage Small-Cell Lung CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Tarlatamab-dznl

Amgen

Phase 3

2 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Trexall

Alnylam Pharmaceuticals

Preclinical

—5

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 6

Viagra

VViatris Specialty LLC

Preclinical

1 7

Duragesic

CCephalon

Preclinical

1 8

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 9

Prednisone/prednisolone

Roche

Preclinical

3 10

Triptorelin Pamoate

Ipsen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Prostate Cancer

NCT07111507

Phase 2Active, not recruiting

Extensive-Stage Small-Cell Lung Cancer

NCT06502977

Q4 2027

Phase 2Active, not recruiting

Small Cell Lung Cancer

NCT05060016

Phase 1Active, not recruiting

Small Cell Lung Cancer

NCT03319940

Phase 2Recruiting

Extensive Stage Lung Small Cell Carcinoma

NCT07423585

Q1 2028

Phase 2Recruiting

Brain Cancer

NCT06776250

Clinical

Trials by Indication[1]

Small Cell Lung Cancer10 trials

Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT07328490·120 enrolled

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

Recruiting· Amgen logo

Amgen·Phase 1·NCT07037758·380 enrolled

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

Active, not recruiting· Amgen logo

Amgen·Phase 1·NCT03319940·269 enrolled

Show 7 more trials

AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)

Completed· Amgen logo

Amgen·Phase 1·NCT04885998·23 enrolled

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

Active, not recruiting· Amgen logo

Amgen·Phase 3·NCT05740566·509 enrolled

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

Recruiting· Amgen logo

Amgen·Phase 1·NCT06898957·200 enrolled

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

Approved for marketing· Amgen logo

Amgen··NCT06064500

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

Active, not recruiting· Amgen logo

Amgen·Phase 2·NCT05060016·222 enrolled

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Active, not recruiting· Amgen logo

Amgen·Phase 1·NCT05361395·184 enrolled

A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)

Recruiting· Amgen logo

Amgen·Phase 3·NCT07005128·330 enrolled

Neuroendocrine Carcinoma5 trials

Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT07016230·40 enrolled

Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients

Recruiting·IInkeun Park·Phase 2·NCT06893783·60 enrolled

Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab

Recruiting·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2·NCT07061080·87 enrolled

Show 2 more trials

Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)

Not yet recruiting·NNational Taiwan University Hospital·Phase 2·NCT06816394·32 enrolled

Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

Recruiting·IIntergroupe Francophone de Cancerologie Thoracique·Phase 3·NCT06937905·129 enrolled

Lung Cancer2 trials

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

Recruiting· Amgen logo

Amgen·Phase 3·NCT06117774·400 enrolled

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

Active, not recruiting· Amgen logo

Amgen·Phase 3·NCT06211036·563 enrolled

Prostate Cancer2 trials

A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer

Completed· Amgen logo

Amgen·Phase 1·NCT04702737·41 enrolled

A Study of Tarlatamab for People With Prostate Cancer

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07111507·32 enrolled

Extensive-stage Small-cell Lung Cancer2 trials

Phase 2a Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of Tarlatamab in Chinese Subjects With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-307)

Active, not recruiting· Amgen logo

Amgen·Phase 2·NCT06502977·32 enrolled

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

Recruiting· Amgen logo

Amgen·Phase 1·NCT06598306·220 enrolled

8 more indications

Tumors1 trial

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Recruiting·UUniversity of Arizona·Phase 1/2·NCT06814496·30 enrolled

Brain Metastases1 trial

Tarlatamab for SCLC Brain Metastases

Not yet recruiting·MMaastricht University Medical Center·Phase 2·NCT07402343·34 enrolled

Brain Cancer1 trial

Study of How Safe and Effective Tarlatamab is in Brain Cancers

Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT06776250·44 enrolled

Central Nervous System Tumor1 trial

Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors

Recruiting·CCentre Leon Berard·Phase 1/2·NCT07243470·70 enrolled

Randomized1 trial

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

Active, not recruiting· Amgen logo

Amgen·Phase 2·NCT06745323·252 enrolled

Extensive Stage Lung Small Cell Cancer1 trial

A Multicentre Phase II Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2

Recruiting·EETOP IBCSG Partners Foundation·Phase 2·NCT07203053·48 enrolled

Limited-stage Small-cell Lung Cancer1 trial

A Phase II Clinical Trial of Tarlatamab as Maintenance Treatment After Sequential Chemo-radiotherapy for Limited Stage SCLC Patients Not Eligible for Concurrent Chemo-radiotherapy

Recruiting·FFundación GECP·Phase 2·NCT07242547·37 enrolled

Extensive Stage Lung Small Cell Carcinoma1 trial

A Front-Line Window-of-Opportunity Phase 2 Study of Tarlatamab (Bispecific T Cell Engager: DLL3-CD3) in Patients With Extensive-Stage Small-Cell Lung Cancer

Recruiting·AAsrar Alahmadi·Phase 2·NCT07423585·39 enrolled

Sources

References

[1]
ClinicalTrials.gov — 29 trial records for Tarlatamab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tarlatamab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tarlatamab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Delta-Like Protein 3 Binding Agent; T Cell Surface Glycoprotein CD3 Binding Agent[2]
Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Amgen

Tarlatamab-dznl

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Q1 2028

Trials by Indication[1]

Small Cell Lung Cancer10 trials

Neuroendocrine Carcinoma5 trials

Lung Cancer2 trials

Prostate Cancer2 trials

Extensive-stage Small-cell Lung Cancer2 trials

Tumors1 trial

Brain Metastases1 trial

Brain Cancer1 trial

Central Nervous System Tumor1 trial

Randomized1 trial

Extensive Stage Lung Small Cell Cancer1 trial

Limited-stage Small-cell Lung Cancer1 trial

Extensive Stage Lung Small Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News